TDMS Study 05136-08 Pathology Tables
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
CORE STUDY
Facility: Battelle Northwest
Chemical CAS #: 0000126-99-8
Lock Date: 04/14/94
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 13 27 38 41
Natural Death 2 6 11 5
Accidently Killed 1 1
Survivors
Terminal Sacrifice 35 16 1 2
Moribund Sacrifice 1
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Colon (50) (47) (48) (49)
Sarcoma 1 (2%)
Intestine Small, Duodenum (49) (45) (42) (48)
Intestine Small, Ileum (50) (45) (46) (49)
Liver (50) (49) (50) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 4 (8%) 10 (20%) 7 (14%) 15 (30%)
Hepatocellular Carcinoma, Multiple 1 (2%) 7 (14%) 4 (8%)
Hepatocellular Adenoma 12 (24%) 12 (24%) 9 (18%) 7 (14%)
Hepatocellular Adenoma, Multiple 5 (10%) 7 (14%) 2 (4%) 9 (18%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 3 (6%)
Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%) 2 (4%)
Mesentery (10) (14) (27) (21)
Hemangioma 2 (7%) 1 (5%)
Hemangiosarcoma 4 (29%) 13 (48%) 4 (19%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (7%)
Histiocytic Sarcoma 1 (4%)
Sarcoma 4 (29%) 8 (30%) 3 (14%)
Pancreas (49) (49) (48) (50)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Mesentery 2 (4%) 2 (4%)
Salivary Glands (50) (49) (50) (50)
Sarcoma, Metastatic, Skin 1 (2%)
Stomach, Forestomach (50) (49) (49) (50)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 4 (8%)
Stomach, Glandular (50) (48) (49) (50)
Sarcoma, Metastatic, Mesentery 1 (2%) 2 (4%) 1 (2%)
Page 2
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (48) (49) (50)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Adrenal Medulla (50) (48) (48) (50)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Islets, Pancreatic (49) (49) (48) (50)
Adenoma 1 (2%) 2 (4%)
Pituitary Gland (49) (48) (48) (50)
Pars Distalis, Adenoma 4 (8%) 6 (13%) 4 (8%) 4 (8%)
Pars Intermedia, Adenoma 1 (2%) 1 (2%)
Thyroid Gland (50) (49) (49) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%)
Follicular Cell, Carcinoma 2 (4%)
Thyroglossal Duct, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (48) (47) (47) (49)
Cystadenoma 1 (2%) 1 (2%) 1 (2%)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Luteoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Teratoma Malignant 1 (2%)
Uterus (50) (49) (50) (50)
Hemangioma 2 (4%)
Hemangiosarcoma 2 (4%)
Histiocytic Sarcoma 1 (2%) 2 (4%) 2 (4%)
Leiomyosarcoma 1 (2%)
Polyp Stromal 2 (4%) 4 (8%) 2 (4%) 3 (6%)
Sarcoma, Metastatic, Mesentery 1 (2%)
Vagina (1)
Page 3
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Sarcoma 1 (100%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Lymph Node (4) (3) (5) (2)
Iliac, Hemangiosarcoma, Metastatic, Mesentery 1 (20%)
Iliac, Sarcoma, Metastatic, Mesentery 1 (50%)
Lymph Node, Bronchial (32) (31) (34) (38)
Histiocytic Sarcoma 1 (3%)
Sarcoma, Metastatic, Mesentery 1 (3%)
Lymph Node, Mandibular (32) (40) (33) (40)
Lymph Node, Mesenteric (48) (45) (48) (46)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%)
Hemangiosarcoma, Metastatic, Mesentery 3 (6%)
Histiocytic Sarcoma 2 (4%)
Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (2%) 4 (8%)
Sarcoma, Metastatic, Skin 1 (2%)
Sarcoma, Metastatic, Intestine Large, Colon 1 (2%)
Lymph Node, Mediastinal (38) (44) (45) (40)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%) 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Sarcoma, Metastatic, Mesentery 1 (3%)
Sarcoma, Metastatic, Skin 1 (3%)
Spleen (50) (49) (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (44) (35) (39) (39)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (50) (50)
Adenoacanthoma 1 (2%) 3 (6%) 2 (4%)
Adenoma 1 (2%) 1 (2%)
Carcinoma 3 (6%) 4 (8%) 6 (12%) 11 (22%)
Carcinoma, Multiple 1 (2%) 1 (2%)
Skin (49) (49) (50) (50)
Basal Cell Adenoma 1 (2%)
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%) 1 (2%)
Page 4
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma 10 (20%) 10 (20%) 16 (32%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) 1 (2%) 2 (4%)
Subcutaneous Tissue, Sarcoma, Metastatic,
Mesentery 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Skeletal Muscle (2) (1)
Sarcoma, Metastatic, Mesentery 1 (50%)
Sarcoma, Metastatic, Skin 1 (50%) 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (49) (50) (50)
Lung (50) (49) (50) (50)
Adenoacanthoma, Metastatic, Mammary Gland 3 (6%)
Alveolar/Bronchiolar Adenoma 2 (4%) 10 (20%) 17 (34%) 10 (20%)
Alveolar/Bronchiolar Adenoma, Multiple 6 (12%) 12 (24%) 16 (32%)
Alveolar/Bronchiolar Carcinoma 2 (4%) 8 (16%) 8 (16%) 11 (22%)
Alveolar/Bronchiolar Carcinoma, Multiple 6 (12%) 8 (16%) 17 (34%)
Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%)
Carcinoma, Metastatic, Mammary Gland 2 (4%) 2 (4%)
Carcinoma, Metastatic, Zymbal's Gland 2 (4%)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%) 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 2 (4%)
Sarcoma, Metastatic, Mesentery 2 (4%) 1 (2%)
Sarcoma, Metastatic, Skin 2 (4%) 1 (2%) 2 (4%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 1 (2%) 2 (4%)
Mediastinum, Hemangiosarcoma 1 (2%)
Mediastinum, Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%)
Mediastinum, Sarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Nose (50) (49) (49) (50)
Respiratory Epithelium, Adenoma 1 (2%)
Page 5
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (6) (4) (9)
Adenoma 1 (50%) 3 (50%) 3 (75%) 8 (89%)
Carcinoma 1 (50%) 2 (33%) 1 (11%)
Zymbal's Gland (3)
Carcinoma 3 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (49) (50)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 2 (4%)
Urinary Bladder (50) (47) (46) (47)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Mesentery 2 (4%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (2%) 2 (4%) 3 (6%)
Lymphoma Malignant 7 (14%) 7 (14%) 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 34 47 50 48
Total Primary Neoplasms 55 124 151 160
Total Animals with Benign Neoplasms 22 32 38 42
Total Benign Neoplasms 31 53 59 66
Total Animals with Malignant Neoplasms 20 42 49 48
Total Malignant Neoplasms 24 71 92 94
Total Animals with Metastatic Neoplasms 3 8 23 15
Total Metastatic Neoplasm 3 18 40 27
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 50 50
Early Deaths
Moribund Sacrifice 15 16 26 34
Natural Death 8 7 10 3
Survivors
Terminal Sacrifice 27 27 14 13
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (41) (40) (37) (40)
Intestine Large, Cecum (48) (44) (45) (48)
Hemangioma 1 (2%)
Muscularis, Leiomyoma 1 (2%)
Intestine Small, Jejunum (46) (43) (47) (49)
Intestine Small, Ileum (46) (45) (46) (48)
Liver (50) (50) (50) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Cholangiocarcinoma 1 (2%)
Hemangiosarcoma 2 (4%) 5 (10%) 6 (12%) 8 (16%)
Hepatoblastoma 2 (4%) 3 (6%) 1 (2%)
Hepatocellular Carcinoma 10 (20%) 18 (36%) 18 (36%) 16 (33%)
Hepatocellular Carcinoma, Multiple 14 (28%) 10 (20%) 19 (38%) 17 (35%)
Hepatocellular Adenoma 8 (16%) 11 (22%) 12 (24%) 11 (22%)
Hepatocellular Adenoma, Multiple 14 (28%) 5 (10%) 7 (14%) 10 (20%)
Hepatocholangiocarcinoma 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma 1 (2%)
Mesentery (2) (8) (16) (11)
Hemangioma 1 (6%) 2 (18%)
Hemangiosarcoma 3 (38%) 13 (81%) 7 (64%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (13%)
Sarcoma, Metastatic, Liver 1 (13%)
Oral Mucosa (1)
Gingival, Squamous Cell Carcinoma 1 (100%)
Pancreas (50) (48) (49) (50)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
Stomach, Forestomach (50) (48) (49) (50)
Squamous Cell Carcinoma 1 (2%)
Page 8
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%) 2 (4%) 4 (8%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%)
Hemangioma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 2 (4%)
Capsule, Adenoma 1 (2%)
Adrenal Medulla (50) (49) (50) (49)
Pheochromocytoma Malignant 1 (2%)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Pituitary Gland (49) (47) (47) (48)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (50) (49) (50) (50)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (49) (50) (50)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%)
Leiomyoma 1 (2%)
Leiomyosarcoma 1 (2%)
Preputial Gland (50) (47) (47) (50)
Hemangiosarcoma 2 (4%)
Prostate (49) (48) (48) (49)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Seminal Vesicle (49) (48) (49) (48)
Sarcoma, Metastatic, Liver 1 (2%)
Testes (50) (49) (50) (50)
Page 9
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Hemangiosarcoma 1 (2%)
Interstitial Cell, Adenoma 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (50) (50)
Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Lymph Node (1) (2) (3)
Renal, Hemangiosarcoma 1 (33%)
Lymph Node, Bronchial (32) (23) (33) (28)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 4 (14%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (4%)
Histiocytic Sarcoma 1 (3%)
Lymph Node, Mandibular (32) (28) (27) (34)
Histiocytic Sarcoma 1 (4%)
Lymph Node, Mesenteric (47) (48) (46) (48)
Hemangiosarcoma 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Lymph Node, Mediastinal (34) (38) (37) (37)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%)
Sarcoma, Metastatic, Liver 1 (3%)
Spleen (50) (49) (50) (50)
Hemangiosarcoma 2 (4%) 2 (4%) 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Thymus (34) (28) (25) (34)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (48) (50) (50)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) 7 (14%)
Subcutaneous Tissue, Hemangiosarcoma,
Multiple 1 (2%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
Page 10
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%)
Skeletal Muscle (1)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Alveolar/Bronchiolar Adenoma 8 (16%) 12 (24%) 15 (30%) 15 (30%)
Alveolar/Bronchiolar Adenoma, Multiple 6 (12%) 7 (14%) 13 (26%)
Alveolar/Bronchiolar Carcinoma 4 (8%) 8 (16%) 13 (26%) 13 (26%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 4 (8%) 10 (20%) 15 (30%)
Hemangiosarcoma, Metastatic, Mesentery 1 (2%)
Hemangiosarcoma, Metastatic, Skin 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%) 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 8 (16%) 10 (20%) 5 (10%) 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%)
Histiocytic Sarcoma 1 (2%)
Sarcoma, Metastatic, Liver 1 (2%)
Bronchiole, Adenoma 1 (2%)
Mediastinum, Alveolar/Bronchiolar Carcinoma,
Metastatic, Lung 4 (8%)
Mediastinum, Hepatocholangiocarcinoma,
Metastatic, Liver 1 (2%) 1 (2%)
Nose (50) (48) (50) (50)
Adenoma 1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Carcinoma, Metastatic, Harderian Gland 1 (2%)
Respiratory Epithelium, Adenoma 1 (2%)
Trachea (50) (48) (50) (50)
Adenoma 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
Page 11
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (2) (5) (11) (12)
Adenoma 2 (100%) 5 (100%) 8 (73%) 9 (75%)
Carcinoma 2 (18%) 2 (17%)
Bilateral, Adenoma 1 (8%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (50) (50)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (2%)
Hemangiosarcoma 1 (2%)
Hemangiosarcoma, Metastatic, Mesentery 4 (8%)
Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Renal Tubule, Adenoma 1 (2%) 1 (2%) 3 (6%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(50) *(50)
Histiocytic Sarcoma 3 (6%) 2 (4%) 1 (2%)
Lymphoma Malignant 2 (4%) 2 (4%) 2 (4%) 4 (8%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 12
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC CHLOROPRENE Date: 10/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 48 50 50
Total Primary Neoplasms 78 106 156 172
Total Animals with Benign Neoplasms 31 31 38 43
Total Benign Neoplasms 38 43 59 72
Total Animals with Malignant Neoplasms 34 40 50 47
Total Malignant Neoplasms 40 63 97 100
Total Animals with Metastatic Neoplasms 8 13 12 12
Total Metastatic Neoplasm 8 22 14 31
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------